Sensome’s new microsensing technology could revolutionize the way strokes are detected and treated, the company’s CEO and co-founder said.
The connected stroke guidewire is designed to sense the composition of clots and relay that information into machine learning algorithms and then on to physicians. Sensome has raised the funds necessary to begin clinical trials.
“We are not aware of any comparable technology,” Franz Bozsak told QMed in July. “Scientists have unsuccessfully tried to identify clots using imaging technologies like MRI or CT scans for years. Knowledge of the clot composition will allow physicians to choose the most effective thrombectomy strategy for a given patient, cutting the time of the intervention to a minimum—meaning in minutes instead of hours—and thus increasing the chances of recovery for the patient after the stroke, as well as cutting costs of the intervention and subsequently the healthcare system.”
Bozsak said the technology can be integrated into a film only 10 micrometers thick, allowing it to be used on any medical device.
He said the technology has been tested in two animal trials. Preclinical testing is scheduled for this fall, with human trials anticipated for 2018.